DK0809996T3 - Interferonkonjugater - Google Patents

Interferonkonjugater

Info

Publication number
DK0809996T3
DK0809996T3 DK97108261T DK97108261T DK0809996T3 DK 0809996 T3 DK0809996 T3 DK 0809996T3 DK 97108261 T DK97108261 T DK 97108261T DK 97108261 T DK97108261 T DK 97108261T DK 0809996 T3 DK0809996 T3 DK 0809996T3
Authority
DK
Denmark
Prior art keywords
interferon
Prior art date
Application number
DK97108261T
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Alicia Vallejo Palleroni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0809996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0809996T3 publication Critical patent/DK0809996T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
DK97108261T 1996-05-31 1997-05-22 Interferonkonjugater DK0809996T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
DK0809996T3 true DK0809996T3 (da) 2003-07-21

Family

ID=21790006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97108261T DK0809996T3 (da) 1996-05-31 1997-05-22 Interferonkonjugater

Country Status (48)

Country Link
US (1) US7201897B2 (da)
EP (1) EP0809996B1 (da)
JP (1) JP2980569B2 (da)
KR (1) KR100254097B1 (da)
CN (1) CN1088721C (da)
AR (1) AR008378A1 (da)
AT (1) ATE235920T1 (da)
AU (1) AU725195B2 (da)
BG (1) BG62273B1 (da)
BR (1) BR9703421A (da)
CA (1) CA2203480C (da)
CO (1) CO4950528A1 (da)
CY (2) CY2433B1 (da)
CZ (1) CZ292775B6 (da)
DE (3) DE809996T1 (da)
DK (1) DK0809996T3 (da)
EG (1) EG24292A (da)
ES (1) ES2110386T3 (da)
GR (1) GR970300063T1 (da)
HK (1) HK1005225A1 (da)
HR (1) HRP970298B1 (da)
HU (1) HU227992B1 (da)
IL (1) IL120902A (da)
IS (1) IS1988B (da)
LU (1) LU91029I2 (da)
MA (1) MA24193A1 (da)
MY (1) MY117909A (da)
NL (1) NL300127I2 (da)
NO (1) NO322964B1 (da)
NZ (1) NZ314903A (da)
OA (1) OA10488A (da)
PA (1) PA8431001A1 (da)
PL (1) PL186949B1 (da)
PT (1) PT809996E (da)
RS (1) RS49533B (da)
RU (1) RU2180595C2 (da)
SA (1) SA97180030B1 (da)
SG (1) SG55314A1 (da)
SI (1) SI0809996T1 (da)
SK (1) SK284458B6 (da)
SV (1) SV1997000049A (da)
TJ (1) TJ328B (da)
TN (1) TNSN97091A1 (da)
TR (1) TR199700358A2 (da)
TW (1) TW517067B (da)
UA (1) UA56989C2 (da)
UY (1) UY24572A1 (da)
ZA (1) ZA974583B (da)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
DE69925820T2 (de) * 1998-03-26 2006-05-18 Schering Corp. Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
SI1421956T1 (sl) * 1998-04-28 2007-10-31 Serono Lab Postopek za stopenjsko vezavo polietilenglikola (peg) na polipeptid
KR100694345B1 (ko) 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 ｃ형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
KR20010052622A (ko) * 1998-06-08 2001-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
NZ514417A (en) * 1999-04-08 2003-10-31 Schering Corp Use of pegylated interferon alpha in chronic myeloid leukemia (CML) therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
PT1043026E (pt) 1999-04-08 2005-09-30 Schering Corp Terapeutica do melanoma
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
US20020009428A1 (en) * 2000-01-24 2002-01-24 Zaknoen Sara L. Combination therapy for cancer
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
ES2286128T3 (es) 2000-06-30 2007-12-01 Zymogenetics, Inc. Proteina zcyto21 tipo interferon.
ATE471956T1 (de) 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
ATE371680T1 (de) * 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
KR100888371B1 (ko) * 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
AU2003240439B2 (en) 2002-06-21 2009-05-21 Novo Nordisk Health Care Ag Pegylated factor VII glycoforms
BR0313212A (pt) 2002-07-24 2005-06-28 Hoffmann La Roche Aditivos de ácido de polialquileno glicol
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
WO2004024761A1 (en) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
ES2314238T3 (es) 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
RU2005118998A (ru) * 2002-11-18 2006-01-27 Максиджен, Инк. (Us) Полипептиды и конъюгаты альфа-интерферона
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
EA010501B1 (ru) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
JP2008507298A (ja) * 2004-05-19 2008-03-13 マキシジェン， インコーポレイテッド インターフェロンαポリペプチドおよび結合体
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
KR20070045244A (ko) 2004-08-12 2007-05-02 쉐링 코포레이션 안정한 페길화된 인터페론 제형
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
AU2006299901A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
WO2007002233A2 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
AU2006315347A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
KR20090021163A (ko) 2006-05-16 2009-02-27 도쿄 메트로폴리탄 오거니제이션 포 메디칼 리서치 Ｈｃｖ 감염증을 치료 또는 예방하기 위한 의약 조성물
JP2009537609A (ja) 2006-05-24 2009-10-29 ノボ ノルディスク ヘルス ケア アーゲー 延長されたｆｉｘアナログ及び誘導体
CN104193815A (zh) 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CN101541955B (zh) 2006-09-08 2016-09-28 Ambrx公司 用于脊椎动物细胞的杂合抑制tRNA
CN1966547B (zh) * 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN101583637B (zh) * 2006-11-07 2012-08-08 帝斯曼知识产权资产管理有限公司 包含生物分子片段的氨基甲酸酯、硫代氨基甲酸酯或尿素
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
US8597635B2 (en) 2007-09-04 2013-12-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha-2B modified by polyethylene glycol and methods of preparation thereof
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
AU2009204998B2 (en) * 2008-01-18 2014-03-27 F. Hoffmann-La Roche Ag Purification of non-glycosylated proteins
PL2237799T3 (pl) * 2008-02-01 2019-09-30 Ascendis Pharma A/S Prolek zawierający samorozszczepiający się łącznik
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
AU2008353850B2 (en) 2008-04-03 2014-08-21 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
ES2521676T3 (es) 2008-07-08 2014-11-13 Board Of Regents, The University Of Texas System Nuevos agentes inhibidores de la proliferación y de la activación de transductores de señales y activadores de la transcripción (STATS)
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
JP5709754B2 (ja) 2008-09-26 2015-04-30 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸による複製に依存する微生物およびワクチン
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EP2493470A1 (en) 2009-10-30 2012-09-05 Boehringer Ingelheim International GmbH Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EP2542569B1 (en) 2010-03-05 2020-09-16 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (zh) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
CN103917240A (zh) 2011-08-03 2014-07-09 叙塞理斯 Hcv免疫疗法
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EA022617B1 (ru) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA023323B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
EP3209316A2 (en) 2014-10-24 2017-08-30 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
ES2966888T3 (es) 2014-11-06 2024-04-24 Pharmaessentia Corp Régimen de dosificación para el interferón pegilado
JP6668468B2 (ja) 2015-11-03 2020-03-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
AU2020223031A1 (en) 2019-02-12 2021-08-19 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
WO1984004745A1 (en) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Novel polypeptides and their use
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
DK0400472T3 (da) * 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5238915A (en) 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
SA97180030B1 (ar) 2005-11-12
AR008378A1 (es) 2000-01-19
ES2110386T1 (es) 1998-02-16
CA2203480A1 (en) 1997-11-30
NL300127I1 (da) 2003-07-01
YU17597A (sh) 1999-07-28
TJ97000465A (en) 1998-12-25
CY2005006I1 (el) 2009-11-04
PL320251A1 (en) 1997-12-08
DE69720320T2 (de) 2004-06-03
HRP970298B1 (en) 2003-08-31
SK67397A3 (en) 1997-12-10
OA10488A (fr) 2002-04-11
GR970300063T1 (en) 1998-01-30
CN1167777A (zh) 1997-12-17
EG24292A (en) 2009-01-08
NO972480D0 (no) 1997-05-30
US7201897B2 (en) 2007-04-10
CZ167997A3 (en) 1997-12-17
BG101540A (en) 1998-02-27
PT809996E (pt) 2003-06-30
CY2005006I2 (el) 2009-11-04
UY24572A1 (es) 2000-12-29
EP0809996B1 (en) 2003-04-02
KR100254097B1 (ko) 2000-05-01
DE809996T1 (de) 1998-04-09
JP2980569B2 (ja) 1999-11-22
US20040030101A1 (en) 2004-02-12
NL300127I2 (nl) 2003-09-01
LU91029I2 (fr) 2004-01-23
AU2372397A (en) 1997-12-04
IS4491A (is) 1997-12-01
IL120902A (en) 2004-06-20
TJ328B (en) 2001-12-24
HUP9700959A2 (hu) 1998-03-02
BG62273B1 (bg) 1999-07-30
CZ292775B6 (cs) 2003-12-17
EP0809996A3 (en) 1999-04-14
NZ314903A (en) 1998-10-28
TNSN97091A1 (fr) 2005-03-15
IS1988B (is) 2005-02-15
TW517067B (en) 2003-01-11
HU9700959D0 (en) 1997-07-28
JPH1067800A (ja) 1998-03-10
ATE235920T1 (de) 2003-04-15
RS49533B (sr) 2006-12-15
DE69720320D1 (de) 2003-05-08
RU2180595C2 (ru) 2002-03-20
PA8431001A1 (es) 2000-05-24
ZA974583B (en) 1998-11-17
CA2203480C (en) 2009-06-30
HRP970298A2 (en) 1998-04-30
DE10399018I1 (de) 2003-10-23
SI0809996T1 (en) 2003-08-31
AU725195B2 (en) 2000-10-05
ES2110386T3 (es) 2003-10-01
CN1088721C (zh) 2002-08-07
EP0809996A2 (en) 1997-12-03
HUP9700959A3 (en) 1998-03-30
CO4950528A1 (es) 2000-09-01
NO322964B1 (no) 2006-12-18
SG55314A1 (en) 1998-12-21
MX9704012A (es) 1997-11-29
SV1997000049A (es) 1998-07-09
PL186949B1 (pl) 2004-04-30
HU227992B1 (en) 2012-08-28
KR970074791A (ko) 1997-12-10
NO972480L (no) 1997-12-01
TR199700358A3 (tr) 1997-12-21
IL120902A0 (en) 1997-09-30
CY2433B1 (en) 2004-11-12
MY117909A (en) 2004-08-30
UA56989C2 (uk) 2003-06-16
MA24193A1 (fr) 1997-12-31
BR9703421A (pt) 1998-09-15
HK1005225A1 (en) 1998-12-31
SK284458B6 (sk) 2005-04-01
TR199700358A2 (xx) 1997-12-21

Similar Documents

Publication Publication Date Title
DK0809996T3 (da) Interferonkonjugater
DK0736303T3 (da) Interferonopløsning
ATE262512T1 (de) Arylalkanoylpyridazine
ATE208773T1 (de) Chinoxalindione
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
NO974125D0 (no) N-benzylazoliumderivater
ID16384A (id) Larutan interferon
KR970050198U (ko) 개량감지기
BR9600867A (pt) Conjunto empacotadora-enfardadora
ATE267568T1 (de) Epithese
BR7601310U (pt) Microlivro
BR7603380U (pt) Abratporta
BR7600260U (pt) Multi-morsa
BR7600429U (pt) Hidrolax
FI963193A0 (fi) Demokrator
BR7601419U (pt) Mourao
BR7601508U (pt) Cogafa
BR7601509U (pt) Gafa
BR7601548U (pt) Tomadamax
BR7601720U (pt) Paraglayder
BR7601926U (pt) Sofá-mesa
BR7602320U (pt) Supedânea
BR7603088U (pt) Kitgeométrico
BR7603126U (pt) Bate - estacas
BR7603147U (pt) Simborgueup